Objective Combination of nanoparticle with p53 and Rb gene therapy by gene targeting was applied to investigate its curative effect and safety evaluation on colorectal rabbit hepatic VX2 metastasis for tumor eradication and survival enhancement. Methods Recombinant expressing plasmids harboring wild type p53 and Rb were cotransferred or transferred separately to the rabbit hepatic VX2 metastasis by the emulsion of PLL-nHAP nanoplex and lipodiol through the hepatic artery in a tumor target manner. Subsequent co-expressions of p53 and Rb protein within the treated tumors were detected by Western blot and in situ analysis of confocal laser scanning microscope. The therapeutic effect was evaluated by the tumor growth velocity and the survival time of animals. Eventually, investigations of liver function were applied to evaluate the safety of the process. Results With safe procedure for the rabbits liver function, both p53 and Rb local nano-therapy showed favorable anti-tumor effects and increased animal survival time. p53+Rb local nano-therapy could significantly inhibit hepatic VX2 metastasis and enhance the animal survival time compared with p53 local nano-therapy or Rb local nano-therapy. Local nano-therapy showed no significant influence to animal liver function. Conclusions Rb can work synergistically with p53 in the combined therapy mediated by PLL-nHAP nanoplex to augment the anti-tumor effect. The local nano-therapy with p53 and Rb is likely to be an effective and safe anti-tumor therapy for hepatic colorectal metastasis.

ObjectiveTo realize the relevance between hypertension and serum uric acid (SUA) in residents in Baise City.MethodsTwenty one thousand,five hundred and eighty eight Baise residents were examined.The body weight,height,waist circumference,hip circumference,blood pressure(BP) were recorded and blood lipidlevels,blood glucoseand serum uric acid (SUA) were tested.The relevance between hypertension and hyperuricemia (HUA) was analyzed by multi-factor variance analysis,x2 test,t test,linear regression and Logistic regression analysis.ResultsHypertension prevalence rate was 31.5％,the frequency of HUA was 12.0％,and 5.8％ residents had both.For patients with both hypertension and HUA,when compared to those with normal serum uric level,their mean diastolic blood pressure(DBP) was(84±10),(72±6) mm Hg res-pectively,there mean systolic blood pressure (SBP) was(151±12),(127±6) mm Hg respectively,and pulse pressure (PP) was (50±12),(37±8) mm Hg respectively.The average BMI of those two groups was (23.9±2.6),(21.7±2.4) kg/m2 respectively.The average TC level was (6.0±1.3),(5.2±1.1)mmol/L respectively,the average TG level was(2.3±2.2),(1.5±0.7) mmol/L respectively,and the average LDL-C level was(3.4±1.3),(3.0±1.1) mmol/L respectively.All these parameters were higher than those people without hypertension or HUA(P＜0.01).However,the situation of HDL-C[ (1.2±0.4),(1.5±0.5)mmol/L] was the opposite (P＜0.01).Regression analysis had shown that age,BMI,waist-hip ratio,SUA,blood glucose,TC,TG,HDL-C and LDL-C were independent risk factors for hypertension,while people with HUA was 3.1 times more when compared to those without HUA.The prevalence rate of HUA in people with hypertension was 2.6 times higher than that of the control group.ConclusionHypertension and HUA are two public health problems that prevalent in the residents in Baise City.Obesity,high blood glucose level and hyperlipidemia are thebasis for the development of hypertension and HUA.Hypertension can be the cause of HUA and verse versa.They may have mutual interactions.The adverse effect of HUA on-cardiovascular system should be taken into consideration clinically.

There were 3 000 Zhuangs,1 102 Miaos, and 1 283 Yaos in Baise City of Guangxi,who were enrolled in this population sampling stratfying survey. Height, weight, blood pressure, fasting blood glucose, and lipids were determined, and compared with those of 2 000 Hans of the same town. The prevalence of hypertension and metablic syndrome in Zhuang inhabitants was high, so were the disorders of glycemia and lipidemia, while in Miao and Yao minorities, the prevalences were comparatively lower. The awareness, treatment, and control of hypertension in these minorities were insufficient.

OBJECTIVETo explore the hematopoietic and immunologic reconstitution and transplantation-related complications of HLA one locus mismatched unrelated umbilical cord blood transplantation for the treatment of hematological malignancies.

METHODSTwo children with acute lymphoblastic leukemia received HLA-mismatched unrelated umbilical cord blood transplantation. The conditioning regimens were BU-CTX (case 1) and BU-CTX plus BCNU (case 2). GVHD prophylaxis regimen consisted of cyclosporine (CsA) and mycophenolate mofetil (MMF). The patients received 14.6 x 10(7) nucleated cells/kg with 7.24 x 10(5) CD(34)(+) cells/kg and 16.24 x 10(7) nucleated cells/kg with 21.11 x 10(5) CD(34)(+) cells/kg, respectively.

RESULTSThe two recipients, ANC > 0.5 x 10(9)/L occurred at day 27 and day 17, BPC > 50 x 10(9)/L at day 53 and day 46, the peripheral blood counts normalization at day 60 and day 52, the immune function normalization at day 134 and day 122 and the DNA fingerprinting showing engraftment at day 19 and day 17, respectively. The donor-recipient pair of case 1 was male to female, and the chromosome karyotype of recipients bone marrow and peripheral blood cells showed 100%, 46, XY cells at day 49. Grade II acute graft versus host disease (aGVHD) occurred at day 26 (case 1) and day 21 (case 2). The two recipients have survived for 353 days and 256 days.

CONCLUSIONThe hematopoietic and immunologic reconstitution in umbilical cord blood transplantation were earlier and more durable. The transplantation-related complications were less and aGVHD were milder.

Child, Preschool ; Cyclosporine ; therapeutic use ; DNA Fingerprinting ; DNA, Neoplasm ; genetics ; Female ; Fetal Blood ; cytology ; immunology ; Graft Survival ; drug effects ; immunology ; Graft vs Host Disease ; immunology ; prevention & control ; HLA Antigens ; immunology ; Hematopoietic Stem Cell Transplantation ; Histocompatibility Testing ; Humans ; Immunosuppressive Agents ; therapeutic use ; Infant ; Male ; Mycophenolic Acid ; analogs & derivatives ; therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; genetics ; immunology ; therapy ; Transplantation Conditioning

Objective To investigate the effects of repetitive transcranial magnetic stimulation (rTMS) on motor recovery in patients with incomplete spinal cord injury （SCI）. Methods 22 patients with T5～T12 incomplete spinal cord injury (ASIA C) were randomly divided into rTMS group and control group. 12 ptients in rTMS group were treated with 10Hz rTMS （10×5 s with 2 min interval) on motor cortex and rehabilitation. 10 patients in control group treated with rehabilitation only. They were assessed with ASIA motor score, ASIA pin prick score, ASIA light touch score, range of motion (ROM) of legs in antigravitation position, walking index for spinal cord injury Ⅱ (WISCIⅡ) and functional independence measure (FIM) score before and 4 weeks after treatment. Results There was no difference between two groups with the clinical assessment before treatment （P>0.05）. The ASIA motor score, ROM of legs and FIM score improved in both groups after treatment （P<0.05）. The score of WISCIⅡ also improved in rTMS group （P<0.05）, and ASIA motor score improved more in rTMS group than that of control group （P<0.05）. Conclusion rTMS can facilitate the recovery of the motor and walking function in patient with incomplete spinal cord injury.

Objective: To evaluate the efficacy and safety of maintenance therapy with reduced dose of rhTPO in the patients with primary immune thrombocytopenia (ITP) who attained stable platelet (PLT) counts after daily administration of rhTPO. Methods: Treatment was started with a daily administration of rhTPO (300 U/kg) for 2 consecutive weeks. Patients who attained stable PLT≥50×10⁹/L were enrolled to maintenance therapy starting with every other day administration of rhTPO, then adjusted dose interval to maintain platelet count (30-100) ×10⁹/L. Results: A total of 91 eligible patients were enrolled. Fourteen patients discontinued the study due to noncompliance (12/14) and investigator decision (2/14) . Among 77 patients who completed the study, 38 patients with the administration of rhTPO at every other day or less could maintain PLT≥30×10⁹/L for 12 weeks. The percentage of patients with a platelet response (PLT≥30×10⁹/L) at 4^th week, 8^th week and 12^th week of maintain therapy was 92.6% (63/68) , 82.7% (43/52) and 85.0% (34/40) , respectively. Median platelet counts remained in the range of (70-124) ×10⁹/L. The overall incidence of rhTPO-related adverse events was 7.7%. All the adverse events were generally mild. Conclusion Extending the dose interval of rhTPO is feasible to maintain stable platelet count in the patients with ITP, but the optimal dose interval is uncertain and might vary with individuals.